Skip to main
BTSG

BTSG Stock Forecast & Price Target

BTSG Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 54%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrightSpring Health is favored because its integrated pharmacy-plus-provider model serves clinically complex, sticky patients, with about six chronic conditions and nine medications on average, while its large $1T+ TAM and rising home-based care demand support durable growth. Its pharmacy platform has meaningful upside from limited distribution drugs, oncology and specialty launches, and the company has already won 12 LDDs YTD with about 20 expected in 2026, while EBITDA per Rx grew 44% y/y in 2Q:26. Management’s disciplined capital allocation, leverage target of 2.5x debt/EBITDA or below, expected 2026 CFFO of $600M+ and FCF above $500M, plus AI-driven cost savings and accretive tuck-in M&A, strengthen the earnings outlook.

Bears say

BrightSpring Health is exposed to a difficult operating backdrop where its pharmacy and provider businesses depend heavily on Medicare and Medicaid reimbursement, while state and federal payment changes can pressure rates, margins, and demand. The company also faces meaningful execution risk from labor recruitment and retention, payor scrutiny, drug-related supply and pricing changes, and integration challenges after the recent Amedisys/LHC asset acquisition, all of which can disrupt profitability. Although management expects the IRA EBITDA drag to fall by 50% in 2027 from a $15 million headwind in 2026, the business still carries competitive and regulatory risks in a highly contested specialty and home-based care market.

BTSG has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 54% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BrightSpring Health Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BrightSpring Health Services Inc (BTSG) Forecast

Analysts have given BTSG a Buy based on their latest research and market trends.

According to 13 analysts, BTSG has a Buy consensus rating as of Oct 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BrightSpring Health Services Inc (BTSG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.